Clinical TrialJul 15, 2026, 04:06 PM
SciSparc: NeuroThera Labs Initiates Phase IIb Trial for Tourette Syndrome
AI Summary
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., has initiated a Phase IIb clinical trial for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults. The first trial site is at Hannover Medical School in Germany, with additional sites planned for Yale Child Study Center in the US and Tel Aviv Sourasky Medical Center in Israel. This advancement follows positive safety and efficacy results from a Phase IIa study, which demonstrated an average tic reduction of 21%.
Key Highlights
- SciSparc's subsidiary, NeuroThera Labs, initiated a Phase IIb clinical trial for SCI-110.
- The trial is for the innovative treatment of Tourette Syndrome (TS) in adults.
- The first clinical trial site is at Hannover Medical School in Germany.
- Additional sites include Yale Child Study Center (US) and Tel Aviv Sourasky Medical Center (Israel).
- SCI-110 combines dronabinol with palmitoylethanolamide to reduce tics and comorbid symptoms.
- Previous Phase IIa study showed an average tic reduction of 21% in participants.
- The Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial.
Price Impact
More from SPRC